Clinical Trial: A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07207395) titled 'A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.' on Oct. 02.

Brief Summary: The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.

Study Start Date: April 29

Study Type: INTERVENTIONAL

Condition: Lung Cancer (NSCLC)

Intervention: DRUG: JBI-802

LSD1/HDAC6 Inhibitor

DRUG: Pembrolizumab

PD-1

Recruitment Status: RECRUITING

Sponsor: The Christ Hospital

Information provided by (Responsible Party): Alexander Starodub, The Christ Hospital

D...